NOVOCURE ($NVCR) posted quarterly earnings results on Thursday, July 24th. The company reported earnings of -$0.36 per share, beating estimates of -$0.39 by $0.03. The company also reported revenue of $158,810,000, beating estimates of $157,291,272 by $1,518,728.
You can see Quiver Quantitative's $NVCR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVOCURE Insider Trading Activity
NOVOCURE insiders have traded $NVCR stock on the open market 27 times in the past 6 months. Of those trades, 0 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- FRANK X LEONARD (EVP, Pres., Novocure Oncology) has made 0 purchases and 6 sales selling 45,232 shares for an estimated $824,669.
- ASHLEY CORDOVA (Chief Executive Officer) has made 0 purchases and 3 sales selling 13,494 shares for an estimated $266,126.
- URI WEINBERG (Chief Innovation Officer) has made 0 purchases and 2 sales selling 4,637 shares for an estimated $86,949.
- MUKUND PARAVASTHU (Chief Operating Officer) has made 0 purchases and 4 sales selling 2,606 shares for an estimated $50,291.
- MICHAL NATH PURI (Chief Human Resources Officer) has made 0 purchases and 2 sales selling 1,387 shares for an estimated $27,772.
- NICOLAS LEUPIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 991 shares for an estimated $19,843.
- W ANTHONY VERNON sold 999 shares for an estimated $17,329
- TIMOTHY J SCANNELL sold 999 shares for an estimated $17,299
- GABRIEL LEUNG sold 999 shares for an estimated $17,297
- DAVID HUNG sold 999 shares for an estimated $17,279
- ALLYSON J OCEAN sold 999 shares for an estimated $17,269
- KRISTIN STAFFORD sold 999 shares for an estimated $17,258
- JERYL L HILLEMAN sold 999 shares for an estimated $17,246
- MARTIN J. MADDEN sold 999 shares for an estimated $17,175
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NOVOCURE Hedge Fund Activity
We have seen 105 institutional investors add shares of NOVOCURE stock to their portfolio, and 127 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,781,710 shares (+101.5%) to their portfolio in Q1 2025, for an estimated $49,570,072
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,690,441 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $30,123,658
- MARSHALL WACE, LLP added 1,536,639 shares (+567.1%) to their portfolio in Q1 2025, for an estimated $27,382,906
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,201,784 shares (-71.4%) from their portfolio in Q1 2025, for an estimated $21,415,790
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 1,080,514 shares (+154.0%) to their portfolio in Q1 2025, for an estimated $19,254,759
- QUANTINNO CAPITAL MANAGEMENT LP added 693,613 shares (+235.4%) to their portfolio in Q1 2025, for an estimated $12,360,183
- FEDERATED HERMES, INC. removed 687,912 shares (-75.8%) from their portfolio in Q1 2025, for an estimated $12,258,591
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NOVOCURE Government Contracts
We have seen $10,446,266 of award payments to $NVCR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETICS: $149,246
- EXPRESS REPORT: OPTUNE PLUS TRANSDUCERS: $149,246
- DEVICE: $99,497
- OPTUNE TRANSDUCERS: $99,497
- PROSTHETICS. OPTUNE DEVICE.: $99,497
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NOVOCURE Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 06/27/2025
To track analyst ratings and price targets for NOVOCURE, check out Quiver Quantitative's $NVCR forecast page.
NOVOCURE Price Targets
Multiple analysts have issued price targets for $NVCR recently. We have seen 4 analysts offer price targets for $NVCR in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Kevin DeGeeter from Ladenburg Thalmann set a target price of $30.0 on 07/08/2025
- Jason Bednar from Piper Sandler set a target price of $34.0 on 06/27/2025
- David Nierengarten from Wedbush set a target price of $27.0 on 04/16/2025
- Jessica Fye from JP Morgan set a target price of $28.0 on 04/10/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
